drugset / Trial / NCT04634071

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

NCT04634071

Phase 2 Completed 126 enrolled Joseph Valentino, MD
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Smoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' preferences in smoking cessation therapy will be the principal determinant by providers in developing a three component regimen of pharmaceutical therapy, counseling, and nicotine replacement therapy. This study will identify this cohort's preferences for smoking cessation strategies. We will then examine the impact of utilizing patient preferences upon cessation efficacy by directly comparing cessation success in this study with our recently completed study of the same population using the same tobacco treatments which were randomly assigned.

Timeline

Start
2021-01-12
Primary completion
2026-01-02
Completion
2026-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg
Subject Nicotine Unknown Other
Subject Nicotine Unknown
Subject Varenicline Small molecule 1 mg